¹ú²úÂ鶹¾«Æ·

  • haemophilus.jpg

Haemophilus influenzae

Haemophilus influenzae is a pleomorphic Gram-negative coccobacillus. There are six encapsulated serotypes (designated ‘a’ through ‘f’) that have distinct capsular polysaccharides. Encapsulated and non-encapsulated strains are both potentially pathogenic to humans but differ in their virulence and pathogenic mechanisms. Haemophilus influenzae serotype b (Hib) is the most virulent, followed by serotype a (Hia), which mainly affects children under 2 years of age.

 

Key facts
  • In 2000, prior to widespread introduction of the vaccine in low- and middle-income countries, Hib was responsible for at least 8.13 million cases of serious illness (uncertainty interval [UI] 7.33-13.2 million) in children aged 1-59 months and 371,000 deaths (UI 247,000-527,000) globally.
  • Worldwide in 2015, there were an estimated 934,000 cases (UI 852,000-1,530,000) of Hib pneumonia in children aged 1-59 months and 31,400 cases (UI 13,400-50,800) of meningitis, resulting in 22,600 (UI 15,900-29,700) and 7,300 (RI 2,700-11,300) deaths respectively. In the Region of the Americas, 5,300 cases (UI 4,900-8,700) corresponded to Hib pneumonia, with 2% lethality; and there were 200 cases (UI 100-300) of meningitis, with 30% lethality.
  • An approximately 90% decrease in Hib cases and deaths followed the introduction of conjugated vaccines.
  • Nasopharyngeal colonization by Hib also declined significantly in populations with extensive immunization coverage against the bacteria, due in part to herd immunity conferred by the use of Hib conjugate vaccines.
Fact sheet

The risk of Hi infection is highest in children aged 2 months to 3 years, although it declines after age 2. In developing countries, the highest incidence is in children under 6 months of age; in developed countries the peak is observed between 6 and 12 months of age. In addition to age, certain conditions increase the risk of Hi (as is the case for all respiratory-transmitted microorganisms): environmental factors such as unventilated settings, overcrowding, exposure to tobacco smoke, air pollution, and concurrent upper respiratory infections. People with certain chronic diseases are at increased risk of infection by this bacterium.

Hi distribution is worldwide, with no well-defined seasonality. However, studies in the pre-vaccine era described seasonal trends in temperate climates, where incidence peaked in the autumn and spring.

It is estimated that between 4% and 35% of unimmunized healthy adults may carry Hi in the nasopharynx (nasopharyngeal colonization). The percentage of carriers is highest among pre-schoolers. Hi can remain in the nasopharynx for months.

Hi distribution is worldwide, with no well-defined seasonality. However, studies in the pre-vaccine era described seasonal trends in temperate climates, where incidence peaked in the autumn and spring.

 

WHO position papers on Haemophilus influenzae vaccine


 

vaccine

Prevention and Control

Hib conjugate vaccines have been used since the early 1990s and are considered an extremely effective health intervention. By 2017, 191 countries (98% of WHO Member States) had included these vaccines in their immunization programs. In the Region of the Americas, all countries use this vaccine. With the introduction of the Hib vaccine in the countries of the Region, there was a dramatic decline in invasive disease caused by the bacterium.

All currently authorized Hib vaccines are conjugates, but they differ in the protein conveyor, chemical conjugation method, polysaccharide size, and adjuvant used, which gives them slightly different immune properties: PRP-OMP is conjugated with the protein complex of Neisseria meningitidis; PRP-T is conjugated with tetanus toxoid; and PRP-CRM197 (HbOC) is conjugated with a protein mutant strain of C. diphteriae.

The vaccine has different presentations: as an isolate (monovalent) or combined with other antigens (e.g., meningococcal serogroup C); combined with diphtheria, tetanus, and pertussis (quadrivalent); combined with diphtheria, tetanus, pertussis and hepatitis B (pentavalent); combined with diphtheria, tetanus, acellular pertussis, and inactivated polio (pentavalent); and combined with diphtheria, tetanus, acellular pertussis, hepatitis B, and inactivated polio (hexavalent).

Hib vaccines are available from the ¹ú²úÂ鶹¾«Æ·/WHO Revolving Fund.

Surveillance

¹ú²úÂ鶹¾«Æ· has been coordinating a sentinel surveillance network for pneumonia and bacterial meningitis in the Region of the Americas since 2007. Since 2014, this network has been part of the Global Surveillance Network, led by the World Health Organization. Currently, nine countries and 20 hospitals participate in this network.

SIREVA II

Since 1993, the Region of the Americas has had a network of laboratories for regional surveillance of invasive bacterial disease, initially known as the SIREVA (Regional Vaccine System) network and now as SIREVA II, involving 19 countries. This is a laboratory-based passive surveillance network that identifies the distribution of serotypes/serogroups and patterns of susceptibility to antimicrobial drugs for Streptococcus pneumoniae (pneumococcus), Haemophilus influenzae, and Neisseria meningitidis (meningococcus), the main bacterial agents associated with these invasive processes.

The following figures show the Hi identified by the SIREVA II network in the period 2017-2018.

 

Documents

Communication Materials